Long-acting monoclonal antibody effective against multidrug-resistant HIV
VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment
Research helps explain how vedolizumab antibody therapy leads to sustained viral remission
Monoclonal antibodies show promise for HIV-positive people with limited treatment options
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV
PRO 140 antibody injections maintain viral suppression in phase 2 study
VRC01 antibody delays but does not prevent HIV rebound after antiretroviral treatment interruption
Dose-finding trials of antibody-based drugs for HIV prevention will start soon
